Recent observations cast doubt on the view that cytotoxic T cells play a key role in keeping HIV-1 infection in check, and that it is the decline in this mechanism of immune surveillance that permits progression to AIDS.
The advent of potent anti-HIV-1 drugs has provided good reason to believe that the outcome of HIV-1 infection will now be substantially better for those infected individuals fortunate enough to have access to them. These anti-viral drugs have also provided valuable tools for studying the kinetics of HIV-1 replication and the turnover of infected cells in vivo. In the course of such studies, important clues have emerged about the nature of the target cells supporting active or chronic HIV-1 infection. Much to the surprise of well-meaning immunologists everywhere, however, the new data on virus and HIV-1-infected-cell turnover in vivo challenge the dogma that cytotoxic (CD8) T lymphocytes (CTLs) with the potential to recognize and kill HIV-1-infected cells play an important role in containing virus replication during the chronic phase of the infection, and that the onset of AIDS follows upon the failure of the host cellular immune response.
A little learning
Elucidation of HIV-1 pathogenesis has been greatly facilitated by the development of assays to measure the magnitude of HIV-1 replication in vivo. Sensitive techniques have been developed recently that quantify levels of HIV-1 RNA within virus particles circulating in the plasma of infected individuals. Recent data indicate that the level of viremia (the 'viral load'), as measured by the amount of HIV-1 RNA in the plasma, accurately reflects the extent of virus replication in an infected person [1, 2] . Although lymphoid tissues, such as lymph nodes and other compartments of the reticuloendothelial system, are thought to be the largest reservoirs of virus infection in vivo, virus particles produced in these tissues are released, through as yet unidentified routes, into the peripheral circulation, where they can be readily sampled. Plasma HIV-1 RNA concentrations are thus likely to reflect the level of active virus replication throughout the body, although we do not yet know whether specific compartments, such as the central nervous system, represent sites of infection that are not in communication with the peripheral virus pool.
The use of plasma HIV-1 RNA assays to study the natural history of HIV-1 infection has helped illuminate, at least in broad outline, one of the long-standing mysteries of HIV-1 disease: why do some people progress rapidly to AIDS following their initial infection with HIV-1, whereas others remain healthy for prolonged periods? The rate of decline of CD4 (helper) T cells after initial HIV-1 infection varies considerably from person to person, and is not constant throughout all stages of the infection. Recent data demonstrate clearly that the magnitude of HIV-1 replication is the primary factor driving the depletion of CD4 T cells and disease progression [3, 4] .
An acceleration in the rate of decline of CD4 T-cell numbers heralds the progression of disease, but the virological and immunological events that occur around this time remain obscure. During primary HIV-1 infection, when there are numerous susceptible target cells without a countervailing host immune response, plasma HIV-1 RNA levels can exceed 10 7 copies per milliliter. About the time that detectable levels of HIV-1-specific CTLs emerge, the levels of plasma HIV-1 RNA decline precipitously (by two to three orders of magnitude or more). It is not, however, known whether this association is causal or coincidental (see below). After a period of fluctuation, often lasting six months or so, plasma HIV-1 RNA levels appear to stabilize around a so-called 'set point'.
Different infected individuals display different steady-state levels of viral replication. Those individuals with higher steady-state 'set-point' levels of plasma HIV-1 RNA lose CD4 T cells more quickly, progress to AIDS more rapidly and die sooner than those with lower HIV-1 RNA set-point levels [3, 4] . The determinants of this set point are incompletely understood, but probably include the number of target cells available for infection (a function of the absolute levels of susceptible T cells and macrophages, their state of activation and the expression of specific co-receptor molecules governing virus entry into target cells), the degree of immune activation, and the tropism (specific target cell preference) and replicative vigor (or 'fitness') of the prevailing HIV-1 strain at various times following the initial infection, as well as the effectiveness of the host anti-viral immune responses (Fig. 1 ).
The steady-state level of HIV-1 RNA in the plasma is a function of the rates of production and clearance -the turnover -of the virus in circulation [1, 2] . Effective antiviral therapy perturbs this steady state and allows an assessment of the kinetic events that underlie it. Thus, virus clearance, the magnitude of virus production, and the longevity of virus-producing cells can all be measured. Recent studies in which virus and infected-cell turnover are measured in this way in persons with moderate to advanced HIV-1 disease have shown that a very dynamic process of virus production and clearance underlies the seemingly static steady-state level of HIV-1 virions in the plasma [1, 2] .
Within two weeks of initiation of potent anti-viral therapy, plasma HIV-1 RNA levels were found to fall to ~1% of their initial values [1, 2] . The slope of this initial decline in HIV-1 RNA levels is referred to as the first-phase decay, and reflects the clearance of virus from the circulation and the longevity of recently infected cells. Interestingly, the slope of the first-phase decay is remarkably constant among different individuals (see below). The half-life of virions in circulation is exceedingly short -about six hours. Given such a rapid rate of virus clearance, it is estimated that 10 9 to 10 10 (or more) virions must be produced each day to maintain the steady-state plasma HIV-1 RNA levels typically found in persons with moderate to advanced HIV-1 disease. When new rounds of virus replication are blocked by potent anti-viral drugs, virus production from the vast majority of infected cells (~99%) After the initial rapid decline in plasma RNA levels, a slower, so-called second-phase decay of the remaining 1% of initial plasma HIV-1 RNA levels is seen [5] . The length of this second-phase decay varies between different individuals (lasting ~8-28 days), and is taken to be a reflection of the decline in numbers of chronically-infected macrophages and latently-infected T cells. Most of the residual viremia is thought to arise from infected macrophages that are lost with an average half-life of about two weeks, while the remainder is produced following activation of latently-infected T cells that decay with an average half-life of eight days or so. Within eight weeks of initiation of potent anti-HIV-1 therapy, plasma HIV-1 RNA levels fall below the level of the detection of even the most sensitive plasma HIV-1 RNA assays available (~25 copies per milliliter), indicating that de novo rounds of HIV-1 infection are profoundly suppressed [5] .
Fortunately, this level of suppression of HIV-1 replication appears to be durable (> 14 months and counting!) for patients who adhere to the complex medical regimens demanded by current combination anti-viral therapies. However, even this marked pharmacological interference with HIV-1 replication has not yet been reported to eradicate an established infection. Rare individuals who have been studied after having stopped effective anti-viral therapy following months with undetectable levels of plasma HIV-1 RNA have all shown rapid rebounds in HIV-1 replication. Thus, while the degree to which the host immune response may contain HIV-1 replication during chronic infection is not yet clear, it appears unable to deliver a coup de grace to HIV-1 even in circumstances where virus replication is profoundly inhibited.
When the going was good
Advocates of the importance of CTLs in the control of HIV-1 replication in infected persons point to a variety of evidence to support their position [6] . Firstly, CTLs have been shown to contain and eliminate virus replication in a number of well-studied experimental models. Secondly, the decline in early viremia seen with resolution of primary HIV-1 infection is temporally associated with the appearance of detectable levels of anti-HIV-1 CTLs. Individuals who, on primary infection, manifest an exaggerated, clonally restricted, HIV-1-specific cytotoxic-T-cell response have been reported to progress to disease more rapidly than those those who mount a broader response, presumably because their HIV-specific CD8 T cells are exhausted more rapidly. Thirdly, high levels of anti-HIV-1 CTLs are seen in established HIV-1 infections, and can often be detected directly from the peripheral blood without in vitro stimulation. The detection of anti-viral CTLs in the absence of in vitro stimulation -so-called 'fresh' CTLs -is claimed to be unusual in the wake of most other virus infections.
Lastly, progression of HIV-1 disease has been reported to be heralded by declining levels of anti-viral CTLs, while individuals with slowly progressive HIV-1 infection typically maintain active CTL responses. Yet even the most vocal proponents of the importance of HIV-specific CTLs admit that high levels of HIV-1 replication, and consequent disease progression, often proceed despite detectable CTL responses. Not only does HIV-1 persist in the face of a vigorous immune response, but it continues to exact incremental damage as time goes by. Thus, although the virus and the immune response seem to achieve a stand-off that is in quasi-steady state -that is, population sizes change slowly relative to the rate at which they turnover -there is nevertheless a slow shift of the balance in favor of the virus. Why is this so? A number of hypotheses have been proposed (Fig. 1 ). What they have in common is that each suggests a process that would shift the balance of power in favor of the virus to the detriment of the host.
Decline and fall
Two of these hypotheses make explicit predictions about how fast productively infected cells are cleared within infected individuals. If progression to AIDS results from failing immune surveillance, then one would expect individuals with more advanced disease to clear infected cells more slowly. Conversely, if AIDS results from the virus evolving to complete the life cycle more quickly, and thus kill infected cells more quickly, one would expect infected cells to disappear more quickly in individuals with more advanced disease. When potent anti-viral drugs became available, these ideas were tested, as described above, by comparing the rate of clearance of cell-free virus from treated patients who, before therapy, had different CD4 counts [1, 2] (Fig. 2) . No relationship was found between CD4 count and rate of clearance of free virus, interpreted as indicating that people do not progress to AIDS because their anti-viral immune response fails.
Within a year, Phillips [7] further undermined the view that CTLs play a pivotal role in HIV-1 infection, by pointing out that, as HIV-1 needs activated CD4 cells in which to replicate, one might expect primary viremia to terminate simply from the depletion of easily infectable cells. The depletion of susceptible target cells during primary HIV-1 infection would occur as they are lost to the cytopathic effects of virus infection, and the level of ongoing virus replication that could be supported thereafter would depend upon the degree to which the pool of susceptible target cells could be replenished. Thus, inducible anti-viral immune responses may not be necessary to contain the high-level viremia of primary infection. What is more, Phillips [7] was able to cite three studies in which infected individuals did indeed end their primary viremia without mounting detectable specific anti-viral immune responses.
So is the vigorous anti-HIV-1 immune response doing nothing? This was, in fact, never the suggestion. Ho and colleagues' results [1, 2] implied that the effect of an immune response is not correlated with the stage of disease, at least in its moderate to advanced stages, and Phillips' study [7] showed that regulation by immune responses is not the only factor that can keep HIV-1 in check. Nevertheless, the reputation of HIV-1-specific CTLs was besmirched, and it seemed as if failing immune surveillance was becoming increasingly less tenable as the central process underlying the progression of HIV-1 disease.
Scoop
Enter Klenerman et al. [8] to defend the beleaguered immune surveillance hypothesis. In their recent paper [8] , they suggest two scenarios in which free virus would be cleared at similar rates in all people, even if CTL killing were an important, but highly variable, cause of infectedcell clearance. The first possibility requires the existence of a small subset of productively infected cells that cannot be killed by CTL. This leads to two different groups of productively infected cells: target cells, subject to viral cytopathic effects and CTL pressure; and another group, cleared only through viral cytopathic effects. The rate of disappearance of free virus is a combination of the loss rates of these two populations. In people with strong CTL responses, the target group is small and disappears very quickly. In people with poor CTL responses, the target group is larger, and disappears more slowly. For the right combinations of parameter values, these patterns can combine to give similar rates of free virus clearance across a broad range of CTL responsiveness.
The second possibility is that the rate of clearance of free virus does not reflect the rate of clearance of productively infected cells, but rather the rate at which recently infected cells incubate their infection to become producers of virus. To be consistent with the observed data on viral decline, this hypothesis requires that the time from infection to production of virus (or becoming a CTL target, whichever comes sooner) is exponentially distributed, with a mean duration that is long compared to the time it takes for a virus-producing cell to be killed by viral cytopathic effects or CTL killing. This ought to be amenable to testing in a synchronously infected in vitro culture, and efforts towards this end have been initiated recently [9] .
Unconditional surrender?
So, should the immune surveillance hypothesis be reinstated, or does it remain fallen? Fortunately, another testable prediction can be extracted from the intriguing ideas put forward by Klenerman et al. [8] . They suggest that differences in CTL activity, as inferred from the lifespans of infected cells, are hard to detect in HIV-1 infection, because they are masked by the cytopathic effects of the virus. In the fast moving world of HIV-1 research, this prediction had been tested almost before it had been posed, and the pattern observed is, if anything, the opposite of that suggested by Klenerman et al. The decay of free virus has very recently been tracked through the second, slow phase of its post-treatment decay [5] . Rather than becoming slower as disease progresses, the second-phase decay rate is, if anything, faster in patients with lower CD4 counts. Whether this reflects higher levels of cellular activation or increased viral cytopathicity in the later stages of the infection remain to be determined. Once again, however, the immune surveillance hypothesis seems to be in trouble.
Two unproven assumptions have stood at the center of the debate about HIV-1 pathogenesis for more than ten years: first, that CTLs play the pivotal role in regulating the viral load of an infected individual; second, that the failure of such immune-mediated killing of infected cells is the precipitating event that leads to AIDS. Both of these ideas have been rocked in the last two years. The primacy of immune control of viral load is brought into question by the suggestion that primary viremia can terminate in the absence of detectable specific immune responses. Similarly, the suggestion that the failure of immune surveillance is the threshold event that individuals cross as they develop AIDS seems to be inconsistent with data that show no relationship between the rate at which infected individuals clear virus, and the degree of damage already done to their immune system.
We are now left with two possibilities. Either we continue to reject failing immune surveillance as the trigger of AIDS, or we postulate that clearance of chronically infected cells is unrelated to CTL activity. In either case, we must consider that our in vitro assays of immune function may not measure responses that are relevant to the in vivo circumstances of HIV-1 infection, and that there are major aspects of the interaction between HIV-1 and the immune system yet to be discovered [10] . We are brought full circle back to the original question; why, oh why, does the immune system allow HIV-infected cells to go on producing virus week after week after week?
